Edgar Filing: BIOMARIN PHARMACEUTICAL INC - Form 8-K

BIOMARIN PHARMACEUTICAL INC

Form 8-K April 01, 2003

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 31, 2003

BioMarin Pharmaceutical Inc. (Exact name of registrant as specified in its charter)

Delaware 000-26727 68-0397820 (State or other jurisdiction of (Commission (IRS Employer incorporation or organization) File Number) Identification No.)

371 Bel Marin Keys Boulevard, Suite 210, Novato, California 94949 (Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code: (415) 884-6700

Not Applicable

(Former name or former address, if changed since last report)

Item 5. Other Events.

On March 31, 2003, BioMarin Pharmaceutical Inc. (the "Registrant"), issued a press release regarding certain recent events, including updates on the regulatory status of Aldurazyme(R), its Vibrilase(TM) clinical development program and news related to its recent follow-on offering. The Registrant's press release issued on March 31, 2003 is attached hereto as Exhibit 99.1.

- Item 7. Financial Statements, Pro Forma Financial Statements and Exhibits.
 - (a) Financial Statements of Business Acquired.

Not Applicable.

(b) Pro Forma Financial Information.

Not Applicable.

Edgar Filing: BIOMARIN PHARMACEUTICAL INC - Form 8-K

(c) Exhibits.

Exhibit 99.1 Press Release of the Registrant dated March 31, 2003.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

BioMarin Pharmaceutical Inc., a Delaware corporation

Date: March 31, 2003 By: /s/ Louis Drapeau

Louis Drapeau

Chief Financial Officer

EXHIBIT INDEX

Exhibit No. Description

Exhibit 99.1 Press Release of the Registrant dated March 31, 2003.